卡马西平致史蒂文斯–约翰逊综合征1例分析及文献复习
Carbamazepine-Induced Stevens-Johnson Syndrome: A Case Report and Literature Review
DOI: 10.12677/acm.2026.1693123, PDF,   
作者: 杨琳琳：暨南大学第一临床医学院，广东 广州；暨南大学附属第一医院感染科，广东 广州；戴海梅, 梁旭竞*：暨南大学附属第一医院感染科，广东 广州
关键词: 卡马西平；Stevens-Johnson综合征；不良反应；TNF-α抑制剂；Carbamazepine； Stevens Johnson Syndrome (SJS)； Adverse Reactions； TNF-α Inhibitors
摘要: 史蒂文斯–约翰逊综合征(Stevens-Johnson Syndrome, SJS)是一种罕见的、危及生命的严重皮肤粘膜反应性疾病。卡马西平被认为是最常见病因之一。现报道一例71岁男性患者因三叉神经痛服用卡马西平1月余，出现全身多形性红斑、水疱、表皮剥脱及粘膜损伤，最后确诊为卡马西平致HLA-B*1502基因阳性老年患者发生的SJS综合征。停用卡马西平后及时给予糖皮质激素联合肿瘤坏死因子-α (Tumor Necrosis Factor-alpha, TNF-α)抑制剂及其它药物干预，患者明显好转。并且同时进行文献复习，旨加强临床对SJS综合征的及时识别及处理，以及TNF-α抑制剂在SJS治疗中的应用。
Abstract: Stevens-Johnson Syndrome (SJS) is a rare, life-threatening severe cutaneous adverse reaction involving mucocutaneous involvement. Carbamazepine is recognized as one of the most common causative agents. We report the case of 71-year-old male patient with trigeminal neuralgia who had been taking carbamazepine for more than one month. He subsequently presented with clinical features including systemic pleomorphic erythema, skin blisters, epidermal detachment and mucosal involvement. He was finally diagnosed with SJS induced by carbamazepine in an elderly patient positive for the HLA-B*1502 allele. Following immediate discontinuation of carbamazepine, the patient was treated with glucocorticoids combined with a tumor necrosis factor-alpha (TNF-α) inhibitor and other supportive interventions. A literature review was also performed to improve the timely recognition and management of SJS and to guide the application of TNF-α inhibitors in its treatment.
文章引用：杨琳琳, 戴海梅, 梁旭竞. 卡马西平致史蒂文斯–约翰逊综合征1例分析及文献复习[J]. 临床医学进展, 2026, 16(9): 940-944. https://doi.org/10.12677/acm.2026.1693123

参考文献

[1] 刘自强. 卡马西平的毒副作用[J]. 国外医学·神经病学神经外科学分册, 1988(1): 16-18.
[2] 程晓东, 张莹, 胡玉皎, 等. 临床患者检测卡马西平药物基因位点在预防Steven-Johnson综合征和中毒性表皮坏死松解症中的应用[J]. 现代检验医学杂志, 2019, 34(4): 15-17.
[3] Hsiao, Y., Hui, R.C., Wu, T., Chang, W., Hsih, M., Yang, C., et al. (2014) Genotype-Phenotype Association between HLA and Carbamazepine-Induced Hypersensitivity Reactions: Strength and Clinical Correlations. Journal of Dermatological Science, 73, 101-109.
https://doi.org/10.1016/j.jdermsci.2013.10.003
[4] Meng, Q., Gu, H., Zhang, Q., Yi, Z. and Jiang, D. (2023) Carbamazepine Cutaneous Adverse Reactions and HLA Gene Variation in the Chinese Population: A Systematic Review and Meta-Analysis. Pharmacogenomics, 24, 459-474.
https://doi.org/10.2217/pgs-2023-0054
[5] Shah, H., Parisi, R., Mukherjee, E., Phillips, E.J. and Dodiuk-Gad, R.P. (2024) Update on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Diagnosis and Management. American Journal of Clinical Dermatology, 25, 891-908.
https://doi.org/10.1007/s40257-024-00889-6
[6] Creamer, D., Walsh, S.A., Dziewulski, P., Exton, L.S., Lee, H.Y., Dart, J.K.G., et al. (2016) UK Guidelines for the Management of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis in Adults 2016. Journal of Plastic, Reconstructive & Aesthetic Surgery, 69, e119-e153.
https://doi.org/10.1016/j.bjps.2016.01.034
[7] 刘晔, 王文. 卡培他滨致Stevens-Johnson综合征1例分析[J]. 中国医院药学杂志, 2024, 44(2): 237-240.
[8] Chen, C.B., Wang, C.W. and Chung, W.H. (2023) TNF-α Blockade Inhibits Matrix Metalloproteinase 9-Mediated Collagenase Activity in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Journal of Investigative Dermatology, 143, 881-883.
https://doi.org/10.1016/j.jid.2023.03.1652
[9] Caproni, M., Torchia, D., Schincaglia, E., Volpi, W., Frezzolini, A., Schena, D., et al. (2006) Expression of Cytokines and Chemokine Receptors in the Cutaneous Lesions of Erythema Multiforme and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. British Journal of Dermatology, 155, 722-728.
https://doi.org/10.1111/j.1365-2133.2006.07398.x
[10] Nassif, A., Moslehi, H., Le Gouvello, S., Bagot, M., Lyonnet, L., Michel, L., et al. (2004) Evaluation of the Potential Role of Cytokines in Toxic Epidermal Necrolysis. Journal of Investigative Dermatology, 123, 850-855.
https://doi.org/10.1111/j.0022-202x.2004.23439.x
[11] Chu, Y., Xu, M., Dong, X. and Zhou, J. (2024) TNF-α Inhibitors as Therapy for Drug-Induced Severe Cutaneous Adverse Reactions: A Case Series. Journal of Dermatological Treatment, 35, 242-292.
https://doi.org/10.1080/09546634.2024.2422924
[12] Tian, C., Ai, X., Ma, J., Hu, F., Liu, X., Luo, Y., et al. (2022) Etanercept Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Annals of Allergy, Asthma & Immunology, 129, 360-365.e1.
https://doi.org/10.1016/j.anai.2022.05.009
[13] Cao, J., Zhang, X., Xing, X. and Fan, J. (2023) Biologic TNF-Α Inhibitors for Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, and TEN-SJS Overlap: A Study-Level and Patient-Level Meta-Analysis. Dermatology and Therapy, 13, 1305-1327.
https://doi.org/10.1007/s13555-023-00928-w
[14] 许媛媛, 孙志琳, 张秀莲, 等. 卡马西平致HLA-A*3101基因阳性中国汉族人发生Stevens-Johnson综合征1例[J]. 北京大学学报(医学版), 2023, 55(4): 755-757.
[15] Zhang, S., Tang, S., Li, S., Pan, Y. and Ding, Y. (2020) Biologic TNF-Alpha Inhibitors in the Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systemic Review. Journal of Dermatological Treatment, 31, 66-73.
https://doi.org/10.1080/09546634.2019.1577548

为你推荐